New Study From Health Equity Platform Violet and Octave Reveals 145% in Unlocked Inclusive Care Ability And Increased Health Outcomes Violet, the first health equity platform, released a new case ...

MENLO PARK, Calif.--(BUSINESS WIRE)-- Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, ...

(RTTNews) - Novavax, Inc. (NVAX) said its recombinant nanoparticle protein vaccine candidate is being studied in OCTAVE-DUO in the UK to evaluate the safety and immunogenicity of a third COVID-19 ...

Octave Bioscience, Inc., a company offering treatment for multiple sclerosis and other neurodegenerative diseases, said it will conduct a real-world study with its sponsor Biogen (Nasdaq: BIIB) ...

A new clinical trial to determine whether a third dose of vaccine will improve the immune response for people who have weakened immune systems is launching in the UK. The study, OCTAVE DUO, will offer ...

The FINANCIAL — A new clinical trial, OCTAVE DUO, investigates if a third vaccine dose for people with weakened immune systems gives a stronger immune response than two doses, UKRI notes. The £2.2 ...

A major clinical trial has found that an additional COVID 19 vaccine dose led to the majority of clinically extremely vulnerable people mounting defensive antibodies against Covid-19. New research ...

OXFORD, England, Jun 17, 2014 (BUSINESS WIRE) -- PsiOxus Therapeutics Ltd. (PsiOxus), an award-winning biotechnology company developing innovative new treatments for cancer, today announced the first ...

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Novavax' recombinant nanoparticle protein vaccine ...